Home LiteratureArticle Details
PMID: 18471507 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Review

Systemic treatment of colorectal cancer.

Gastroenterology ·Vol. 134 ·No. 5 ·2008-05-00 ·Pages 1296-310

Wolpin BM, Mayer RJ

Abstract

Colorectal cancer is the fourth most common noncutaneous malignancy in the United States and the second most frequent cause of cancer-related death. Over the past 12 years, significant progress has been made in the systemic treatment of this malignant condition. Six new chemotherapeutic agents have been introduced, increasing median overall survival for patients with metastatic colorectal cancer from less than 9 months with no treatment to approximately 24 months. For patients with stage III (lymph node positive) colon cancer, an overall survival benefit for fluorouracil-based chemotherapy has been firmly established, and recent data have shown further efficacy for the inclusion of oxaliplatin in such adjuvant treatment programs. For patients with stage II colon cancer, the use of adjuvant chemotherapy remains controversial, but may be appropriate in a subset of individuals at higher risk for disease recurrence. Ongoing randomized clinical trials are evaluating how best to combine currently available therapies, while smaller studies are evaluating new agents, with the goal of continued progress in prolonging life among patients with metastatic colorectal cancer and increasing cure rates among those with resectable disease.

MeSH Terms
Angiogenesis Inhibitors/administration & dosage,therapeutic use Antineoplastic Agents/administration & dosage,therapeutic use Camptothecin/administration & dosage,analogs & derivatives,therapeutic use Colorectal Neoplasms/drug therapy,pathology ErbB Receptors/antagonists & inhibitors Fluorouracil/administration & dosage,therapeutic use Humans Irinotecan Neoplasm Staging Organoplatinum Compounds/administration & dosage,therapeutic use Oxaliplatin Prodrugs Treatment Outcome
Chemicals
Angiogenesis Inhibitors Antineoplastic Agents Organoplatinum Compounds Prodrugs Oxaliplatin Irinotecan ErbB Receptors Fluorouracil Camptothecin
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Wolpin Brian M
Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Mayer Robert J
References (167)
167 references, click to expand
  1. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.
    J Clin Oncol. 1989 Oct;7(10):1407-18 PMID: 2476530
  2. The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer. Results from NSABP (National Surgical Adjuvant Breast and Bowel Project) clinical trials.
    Ann Surg. 1984 Apr;199(4):375-82 PMID: 6370155
  3. Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy.
    Semin Oncol. 2000 Oct;27(5 Suppl 10):72-7 PMID: 11049035
  4. Preoperative versus postoperative chemoradiotherapy for rectal cancer.
    N Engl J Med. 2004 Oct 21;351(17):1731-40 PMID: 15496622
  5. New tumor-node-metastasis staging strategy for node-positive (stage III) rectal cancer: an analysis.
    J Clin Oncol. 2004 May 15;22(10):1778-84 PMID: 14769855
  6. Relation of hospital volume to colostomy rates and survival for patients with rectal cancer.
    J Natl Cancer Inst. 2003 May 21;95(10):708-16 PMID: 12759388
  7. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.
    J Clin Oncol. 2006 Nov 20;24(33):5313-27 PMID: 17060676
  8. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer.
    J Clin Oncol. 1995 Dec;13(12):2936-43 PMID: 8523058
  9. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports.
    Ann Oncol. 1997 Oct;8(10):1049-51 PMID: 9402181
  10. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.
    J Clin Oncol. 2007 Sep 20;25(27):4217-23 PMID: 17548840
  11. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.
    Clin Cancer Res. 2002 Mar;8(3):641-61 PMID: 11895891
  12. The staging of colorectal cancer: 2004 and beyond.
    CA Cancer J Clin. 2004 Nov-Dec;54(6):295-308 PMID: 15537574
  13. Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer.
    J Natl Cancer Inst. 2002 Aug 7;94(15):1160-7 PMID: 12165641
  14. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.
    N Engl J Med. 2001 Oct 11;345(15):1091-7 PMID: 11596588
  15. Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one?
    Clin Cancer Res. 2007 Aug 15;13(16):4664-6 PMID: 17699842
  16. Underrepresentation of patients 65 years of age or older in cancer-treatment trials.
    N Engl J Med. 1999 Dec 30;341(27):2061-7 PMID: 10615079
  17. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    J Clin Oncol. 2000 Aug;18(16):2938-47 PMID: 10944126
  18. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997.
    Arch Surg. 1998 Aug;133(8):894-9 PMID: 9711965
  19. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03.
    J Clin Oncol. 1993 Oct;11(10):1879-87 PMID: 8410113
  20. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients.
    Ann Oncol. 2008 Apr;19(4):717-23 PMID: 17974556
  21. Molecular prognostic markers in locally advanced colon cancer.
    Clin Colorectal Cancer. 2007 Nov;6(10):683-90 PMID: 18039421
  22. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.
    Health Technol Assess. 2003;7(32):1-93 PMID: 14604497
  23. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials.
    Lancet. 2001 Oct 20;358(9290):1291-304 PMID: 11684209
  24. Oxaliplatin: a review of preclinical and clinical studies.
    Ann Oncol. 1998 Oct;9(10):1053-71 PMID: 9834817
  25. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group.
    J Clin Oncol. 1989 Oct;7(10):1419-26 PMID: 2674331
  26. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer.
    J Clin Oncol. 1997 Jan;15(1):246-50 PMID: 8996149
  27. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Lancet. 2000 Mar 25;355(9209):1041-7 PMID: 10744089
  28. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.
    BMJ. 1993 Mar 20;306(6880):752-5 PMID: 7683942
  29. Actual 10-year survival after resection of colorectal liver metastases defines cure.
    J Clin Oncol. 2007 Oct 10;25(29):4575-80 PMID: 17925551
  30. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group.
    J Clin Oncol. 2004 Aug 15;22(16):3395-407 PMID: 15199087
  31. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
    J Clin Oncol. 2004 Jan 1;22(1):23-30 PMID: 14665611
  32. The price tag on progress--chemotherapy for colorectal cancer.
    N Engl J Med. 2004 Jul 22;351(4):317-9 PMID: 15269308
  33. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    N Engl J Med. 2004 Jun 3;350(23):2335-42 PMID: 15175435
  34. Capecitabine as adjuvant treatment for stage III colon cancer.
    N Engl J Med. 2005 Jun 30;352(26):2696-704 PMID: 15987918
  35. Adjuvant chemotherapy in cancer of the colon and rectum: demonstration of effectiveness of prolonged 5-FU chemotherapy in a prospectively controlled, randomized trial.
    Surg Clin North Am. 1981 Dec;61(6):1321-9 PMID: 6171898
  36. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
    J Clin Oncol. 2004 Apr 1;22(7):1209-14 PMID: 15051767
  37. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.
    J Clin Oncol. 2007 Apr 20;25(12):1539-44 PMID: 17442997
  38. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.
    J Clin Oncol. 2004 Apr 1;22(7):1201-8 PMID: 14993230
  39. Cost of cancer care: issues and implications.
    J Clin Oncol. 2007 Jan 10;25(2):180-6 PMID: 17210937
  40. A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients.
    Ann Surg. 2002 Oct;236(4):416-21; discussion 421 PMID: 12368669
  41. Cancer statistics, 1992.
    CA Cancer J Clin. 1992 Jan-Feb;42(1):19-38 PMID: 1728335
  42. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older.
    J Clin Oncol. 1999 Aug;17(8):2412-8 PMID: 10561304
  43. Survival after postoperative combination treatment of rectal cancer.
    N Engl J Med. 1986 Nov 13;315(20):1294-5 PMID: 3773947
  44. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.
    J Clin Oncol. 2007 Jun 1;25(16):2205-11 PMID: 17470850
  45. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort.
    J Clin Oncol. 2003 Apr 1;21(7):1293-300 PMID: 12663717
  46. Determinants of black/white differences in colon cancer survival.
    J Natl Cancer Inst. 1995 Nov 15;87(22):1686-93 PMID: 7473817
  47. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
    J Clin Oncol. 2005 May 20;23(15):3502-8 PMID: 15908660
  48. Adjuvant therapy of colorectal cancer. Why we still don't know.
    JAMA. 1988 Jun 24;259(24):3571-8 PMID: 3286920
  49. Explaining black-white differences in receipt of recommended colon cancer treatment.
    J Natl Cancer Inst. 2005 Aug 17;97(16):1211-20 PMID: 16106026
  50. Cetuximab for the treatment of colorectal cancer.
    N Engl J Med. 2007 Nov 15;357(20):2040-8 PMID: 18003960
  51. A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis.
    Eur J Cancer. 2005 Sep;41(14):2060-70 PMID: 16125380
  52. The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined.
    Ann Surg Oncol. 2003 Jan-Feb;10(1):65-71 PMID: 12513963
  53. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    J Clin Oncol. 2004 Jan 15;22(2):229-37 PMID: 14657227
  54. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.
    J Clin Oncol. 1998 Jan;16(1):301-8 PMID: 9440757
  55. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis.
    J Clin Oncol. 2004 Sep 15;22(18):3766-75 PMID: 15365073
  56. Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02.
    J Clin Oncol. 1990 Sep;8(9):1466-75 PMID: 2202789
  57. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    J Clin Oncol. 2001 Apr 15;19(8):2282-92 PMID: 11304782
  58. Molecular predictors of survival after adjuvant chemotherapy for colon cancer.
    N Engl J Med. 2001 Apr 19;344(16):1196-206 PMID: 11309634
  59. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
    J Clin Oncol. 2002 Sep 1;20(17):3605-16 PMID: 12202661
  60. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04.
    J Clin Oncol. 1999 Nov;17(11):3553-9 PMID: 10550154
  61. Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion. A study of the Mayo Clinic and the North Central Cancer Treatment Group.
    Arch Surg. 1990 Jul;125(7):897-901 PMID: 2369315
  62. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.
    Lancet. 1998 Oct 31;352(9138):1413-8 PMID: 9807987
  63. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group.
    Cancer. 2000 Apr 1;88(7):1739-57 PMID: 10738234
  64. Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma.
    Lancet. 1992 Aug 29;340(8818):502-6 PMID: 1354275
  65. Prognosis after rectal cancer in blacks and whites participating in adjuvant therapy randomized trials.
    J Clin Oncol. 2003 Feb 1;21(3):413-20 PMID: 12560428
  66. Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan.
    Invest New Drugs. 2005 Dec;23(6):539-45 PMID: 16267624
  67. Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control. Results of a prospective randomized clinical trial (colorectal adenocarcinoma trial I).
    Cancer. 1990 Feb 1;65(3):425-32 PMID: 2404556
  68. Impact of number of nodes retrieved on outcome in patients with rectal cancer.
    J Clin Oncol. 2001 Jan 1;19(1):157-63 PMID: 11134208
  69. Why the epidermal growth factor receptor? The rationale for cancer therapy.
    Oncologist. 2002;7 Suppl 4:2-8 PMID: 12202782
  70. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
    J Clin Oncol. 2007 Oct 20;25(30):4779-86 PMID: 17947725
  71. The tea leaves of small trials.
    J Clin Oncol. 1999 May;17(5):1336-8 PMID: 10334516
  72. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089.
    J Clin Oncol. 2003 Aug 1;21(15):2912-9 PMID: 12885809
  73. Oral fluoropyrimidines in the treatment of colorectal cancer.
    Eur J Cancer. 1998 Sep;34(10):1509-13 PMID: 9893621
  74. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer.
    Cancer. 1993 Apr 15;71(8):2454-60 PMID: 8095852
  75. Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer.
    Anticancer Drugs. 2006 Aug;17(7):855-7 PMID: 16926635
  76. Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
    J Clin Oncol. 2007 Sep 20;25(27):4165-7 PMID: 17709796
  77. Systemic therapy for colorectal cancer.
    N Engl J Med. 2005 Feb 3;352(5):476-87 PMID: 15689586
  78. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.
    Lancet. 1998 Oct 31;352(9138):1407-12 PMID: 9807986
  79. Intraluminal fluorouracil chemotherapy adjunct to surgical procedures for respectable carcinoma of the colon and rectum.
    Surg Gynecol Obstet. 1977 Oct;145(4):549-54 PMID: 331522
  80. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.
    J Clin Oncol. 2007 Oct 10;25(29):4557-61 PMID: 17876013
  81. Effective surgical adjuvant therapy for high-risk rectal carcinoma.
    N Engl J Med. 1991 Mar 14;324(11):709-15 PMID: 1997835
  82. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.
    J Clin Oncol. 2004 Aug 15;22(16):3408-19 PMID: 15199089
  83. A double-blind comparison of intensive course 5-flourouracil by oral vs. intravenous route in the treatment of colorectal carcinoma.
    Cancer. 1975 Apr;35(4):1031-5 PMID: 1090358
  84. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.
    J Clin Oncol. 2005 Dec 1;23(34):8671-8 PMID: 16314627
  85. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
    J Clin Oncol. 2007 Jun 1;25(16):2198-204 PMID: 17470851
  86. Adjuvant Treatment of Colorectal Cancer in the Elderly.
    Cancer Control. 1995 Mar;2(2 Suppl 1):36-38 PMID: 10887408
  87. A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer.
    Br J Surg. 1985 May;72(5):359-63 PMID: 3888335
  88. Vascular and neural invasion in colorectal carcinoma. Incidence and prognostic significance.
    Cancer. 1988 Mar 1;61(5):1018-23 PMID: 3338045
  89. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer.
    Ann Oncol. 2006 Feb;17(2):239-45 PMID: 16344278
  90. Modulation of fluoropyrimidines: role of dose and schedule of leucovorin administration.
    Semin Oncol. 1992 Apr;19(2 Suppl 3):10-5 PMID: 1532669
  91. Impact of surgical and pathologic variables in rectal cancer: a United States community and cooperative group report.
    J Clin Oncol. 2001 Sep 15;19(18):3895-902 PMID: 11559727
  92. Influence of hospital procedure volume on outcomes following surgery for colon cancer.
    JAMA. 2000 Dec 20;284(23):3028-35 PMID: 11122590
  93. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
    J Clin Oncol. 2007 May 1;25(13):1658-64 PMID: 17470858
  94. Aging and cancer in America. Demographic and epidemiologic perspectives.
    Hematol Oncol Clin North Am. 2000 Feb;14(1):17-23 PMID: 10680069
  95. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer).
    N Engl J Med. 2005 May 5;352(18):1851-60 PMID: 15872200
  96. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report.
    Ann Intern Med. 1995 Mar 1;122(5):321-6 PMID: 7847642
  97. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial.
    J Clin Oncol. 2003 Aug 1;21(15):2896-903 PMID: 12885807
  98. Uracil-ftorafur: an oral fluoropyrimidine active in colorectal cancer.
    J Clin Oncol. 1998 Oct;16(10):3461-75 PMID: 9779725
  99. Adjuvant therapy for large bowel cancer: update of Veterans Administration Surgical Oncology Group Trials.
    Surg Clin North Am. 1981 Dec;61(6):1311-20 PMID: 7031937
  100. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
    Lancet. 2007 Dec 15;370(9604):2020-9 PMID: 18083404
  101. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
    N Engl J Med. 2004 Jun 3;350(23):2343-51 PMID: 15175436
  102. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes.
    J Clin Oncol. 2005 Dec 1;23(34):8706-12 PMID: 16314630
  103. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
    J Clin Oncol. 2002 Sep 1;20(17):3617-27 PMID: 12202662
  104. Adjuvant chemotherapy in the surgical treatment of large bowel cancer.
    Cancer. 1976 Oct;38(4):1461-7 PMID: 791471
  105. Racial differences in colorectal cancer mortality. The importance of stage and socioeconomic status.
    J Clin Epidemiol. 2001 Apr;54(4):359-66 PMID: 11297886
  106. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
    J Clin Oncol. 2007 Aug 1;25(22):3230-7 PMID: 17664471
  107. Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges.
    Cancer. 1996 Jul 15;78(2):294-9 PMID: 8674006
  108. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?
    J Clin Oncol. 2005 Aug 1;23(22):5235-46 PMID: 16051966
  109. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale.
    J Clin Oncol. 2005 Aug 1;23(22):4866-75 PMID: 15939922
  110. A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma.
    J Clin Oncol. 1985 Dec;3(12):1624-31 PMID: 2933492
  111. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.
    J Clin Oncol. 2007 Sep 20;25(27):4224-30 PMID: 17548839
  112. A renewed call for equipoise.
    J Clin Oncol. 2007 Aug 10;25(23):3392-4 PMID: 17687146
  113. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab.
    J Clin Oncol. 2007 Aug 1;25(22):3238-45 PMID: 17664472
  114. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.
    N Engl J Med. 1990 Feb 8;322(6):352-8 PMID: 2300087
  115. Oxaliplatin: mechanism of action and antineoplastic activity.
    Semin Oncol. 1998 Apr;25(2 Suppl 5):4-12 PMID: 9609103
  116. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study.
    Ann Oncol. 1998 Jan;9(1):105-8 PMID: 9541691
  117. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas.
    Tumour Biol. 2000 Mar-Apr;21(2):105-15 PMID: 10686540
  118. Reversible posterior leukoencephalopathy syndrome and bevacizumab.
    N Engl J Med. 2006 Mar 2;354(9):980-2; discussion 980-2 PMID: 16510760
  119. Comparison of costs for infusion versus bolus chemotherapy administration--Part two. Use of charges versus reimbursement for cost basis.
    Cancer. 1996 Jul 15;78(2):300-3 PMID: 8674007
  120. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.
    J Clin Oncol. 2003 Jun 1;21(11):2059-69 PMID: 12775730
  121. Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study.
    J Clin Oncol. 2004 Jan 1;22(1):166-74 PMID: 14701779
  122. Tumor angiogenesis: therapeutic implications.
    N Engl J Med. 1971 Nov 18;285(21):1182-6 PMID: 4938153
  123. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
    J Clin Oncol. 2005 Jun 1;23(16):3706-12 PMID: 15867200
  124. Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. Liver Infusion Meta-analysis Group.
    J Natl Cancer Inst. 1997 Apr 2;89(7):497-505 PMID: 9086006
  125. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery.
    N Engl J Med. 1994 Aug 25;331(8):502-7 PMID: 8041415
  126. The rational development of capecitabine from the laboratory to the clinic.
    Anticancer Res. 2002 Nov-Dec;22(6B):3589-96 PMID: 12552961
  127. The biology of VEGF and its receptors.
    Nat Med. 2003 Jun;9(6):669-76 PMID: 12778165
  128. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
    N Engl J Med. 2000 Sep 28;343(13):905-14 PMID: 11006366
  129. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer.
    Ann Oncol. 2005 Apr;16(4):549-57 PMID: 15695501
  130. Epidermal growth factor receptor expression and measurement in solid tumors.
    Semin Oncol. 2002 Oct;29(5 Suppl 14):45-54 PMID: 12422313
  131. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802).
    Ann Oncol. 2009 Apr;20(4):674-80 PMID: 19179549
  132. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer.
    Ann Intern Med. 2002 Mar 5;136(5):349-57 PMID: 11874307
  133. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer.
    J Clin Oncol. 2005 Mar 20;23(9):1819-25 PMID: 15774775
  134. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer.
    N Engl J Med. 2000 Jan 13;342(2):69-77 PMID: 10631274
  135. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
    J Clin Oncol. 1999 May;17(5):1349-55 PMID: 10334518
  136. Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Swiss Group for Clinical Cancer Research (SAKK)
    Lancet. 1995 Feb 11;345(8946):349-53 PMID: 7845115
  137. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging.
    J Natl Cancer Inst. 2004 Oct 6;96(19):1420-5 PMID: 15467030
  138. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.
    J Clin Oncol. 2006 May 1;24(13):2059-64 PMID: 16648506
  139. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.
    J Clin Oncol. 2000 Jan;18(1):136-47 PMID: 10623704
  140. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
    J Clin Oncol. 2003 Jan 1;21(1):60-5 PMID: 12506171
  141. Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer.
    Br J Surg. 1987 Jul;74(7):569-72 PMID: 3304518
  142. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
    J Clin Oncol. 2004 May 15;22(10):1797-806 PMID: 15067028
  143. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.
    J Clin Oncol. 2008 Jan 20;26(3):374-9 PMID: 18202412
  144. Sequential chemoimmunotherapy of colorectal cancer: evaluation of methotrexate, Baker's Antifol and levamisole.
    Cancer. 1978 Nov;42(5):2169-76 PMID: 363254
  145. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer.
    Gastroenterology. 1994 Apr;106(4):899-906 PMID: 8143995
  146. Palliative chemotherapy for advanced or metastatic colorectal cancer. Colorectal Meta-analysis Collaboration.
    Cochrane Database Syst Rev. 2000;(2):CD001545 PMID: 10796809
  147. Cellular and molecular pharmacology of oxaliplatin.
    Mol Cancer Ther. 2002 Jan;1(3):227-35 PMID: 12467217
  148. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.
    N Engl J Med. 2001 Aug 30;345(9):638-46 PMID: 11547717
  149. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.
    J Clin Oncol. 2003 Oct 15;21(20):3721-8 PMID: 12963704
  150. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
    N Engl J Med. 2004 Jul 22;351(4):337-45 PMID: 15269313
  151. Age and adjuvant chemotherapy use after surgery for stage III colon cancer.
    J Natl Cancer Inst. 2001 Jun 6;93(11):850-7 PMID: 11390534
  152. Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer.
    N Engl J Med. 1978 Aug 31;299(9):448-51 PMID: 683276
  153. EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma.
    Acta Oncol. 1998;37(3):285-9 PMID: 9677101
  154. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer.
    J Clin Oncol. 1998 Jan;16(1):295-300 PMID: 9440756
  155. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    J Clin Oncol. 2001 Nov 1;19(21):4097-106 PMID: 11689577
  156. Colorectal cancer and race: understanding the differences in outcomes between African Americans and whites.
    Med Clin North Am. 2005 Jul;89(4):771-93 PMID: 15925649
  157. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
    Clin Cancer Res. 2001 Aug;7(8):2182-94 PMID: 11489791
  158. Survival of blacks and whites after a cancer diagnosis.
    JAMA. 2002 Apr 24;287(16):2106-13 PMID: 11966385
  159. Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma.
    Cancer. 2005 Jun 15;103(12):2435-46 PMID: 15880563
  160. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.
    J Clin Oncol. 2005 Mar 20;23(9):1803-10 PMID: 15677699
  161. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.
    J Clin Oncol. 1998 Aug;16(8):2739-44 PMID: 9704726
  162. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer.
    J Clin Oncol. 2002 Oct 1;20(19):3992-8 PMID: 12351596
  163. Prolongation of the disease-free interval in surgically treated rectal carcinoma.
    N Engl J Med. 1985 Jun 6;312(23):1465-72 PMID: 2859523
  164. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.
    J Clin Oncol. 1997 Feb;15(2):808-15 PMID: 9053508
  165. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.
    J Clin Oncol. 2007 Aug 10;25(23):3456-61 PMID: 17687149
  166. Cancer statistics, 2007.
    CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 PMID: 17237035
  167. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation.
    JAMA. 2005 Dec 7;294(21):2703-11 PMID: 16333005
Article Info
Journal
Gastroenterology
Abbr.
Gastroenterology
ISSN
1528-0012
DOI
10.1053/j.gastro.2008.02.098
Published
2008-05-00
Pages
1296-310
Language
English
Region
United States
NLM ID
0374630
PMCID
PMC2528832
Subset
IM
Grants
NCI NIH HHS · T32 CA009172 · United States
NCI NIH HHS · T32 CA009172-34 · United States
NCI NIH HHS · T32CA09001 · United States
NCI NIH HHS · IP50CA127003-01 · United States
External Links
PubMed source DOI: 10.1053/j.gastro.2008.02.098 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2